NICOTINAMIDE ADENINE DINUCLEOTIDE 1G & RETATRUTIDE : A UNITED KINGDOM UPDATE

The growing interest in NAD+ supplementation, particularly at a high dosage of 1g , continues to gain momentum within the UK healthcare community. Concurrently, attention is firmly fixed on Retatrutide, a innovative GLP-1 receptor agonist being viewed by many as a potential successor to Tirzepati